Evidence map›Paper›PMID 27347635›Full record

ReviewCritical reviews in toxicology2016

A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.

Katie Paul Friedman, Sabitha Papineni, M Sue Marty, Kun Don Yi, Amber K Goetz, Reza J Rasoulpour, Pat Kwiatkowski, Douglas C Wolf, Ann M Blacker, Richard C Peffer

Abstract readReview
In one paragraph

Review in Critical reviews in toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Profiling the endocrine-disrupting properties of triazines, triazoles, and short-chain PFAS.Toxicological sciences : an official journal of the Society of Toxicology · 2024
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Katie Paul Friedmana Human Safety, Bayer CropScience LP, Research Triangle Park , NC , USA ;
Sabitha Papinenib Human Health Assessment, Dow AgroSciences LLC , Indianapolis , IN , USA ;
M Sue Martyc Toxicology & Environmental Research and Consulting, The Dow Chemical Company , Midland , MI , USA ;
Kun Don Yid Toxicology and Health Sciences, Syngenta Crop Protection LLC , Greensboro , NC , USA.
Amber K Goetzd Toxicology and Health Sciences, Syngenta Crop Protection LLC , Greensboro , NC , USA.
Reza J Rasoulpourb Human Health Assessment, Dow AgroSciences LLC , Indianapolis , IN , USA ;
Pat Kwiatkowskia Human Safety, Bayer CropScience LP, Research Triangle Park , NC , USA ;
Douglas C Wolfd Toxicology and Health Sciences, Syngenta Crop Protection LLC , Greensboro , NC , USA.
Ann M Blackera Human Safety, Bayer CropScience LP, Research Triangle Park , NC , USA ;
Richard C Pefferd Toxicology and Health Sciences, Syngenta Crop Protection LLC , Greensboro , NC , USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The US Environmental Protection Agency Endocrine Disruptor Screening Program (EDSP) is a tiered screening approach to determine the potential for a chemical to interact with estrogen, androgen, or thyroid hormone systems and/or perturb steroidogenesis. Use of high-throughput screening (HTS) to predict hazard and exposure is shifting the EDSP approach to (1) prioritization of chemicals for further screening; and (2) targeted use of EDSP Tier 1 assays to inform specific data needs. In this work, toxicology data for three triazole fungicides (triadimefon, propiconazole, and myclobutanil) were evaluated, including HTS results, EDSP Tier 1 screening (and other scientifically relevant information), and EPA guideline mammalian toxicology study data. The endocrine-related bioactivity predictions from HTS and information that satisfied the EDSP Tier 1 requirements were qualitatively concordant. Current limitations in the available HTS battery for thyroid and steroidogenesis pathways were mitigated by inclusion of guideline toxicology studies in this analysis. Similar margins (3-5 orders of magnitude) were observed between HTS-predicted human bioactivity and exposure values and between in vivo mammalian bioactivity and EPA chronic human exposure estimates for these products' registered uses. Combined HTS hazard and human exposure predictions suggest low priority for higher-tiered endocrine testing of these triazoles. Comparison with the mammalian toxicology database indicated that this HTS-based prioritization would have been protective for any potential in vivo effects that form the basis of current risk assessment for these chemicals. This example demonstrates an effective, human health protective roadmap for EDSP evaluation of pesticide active ingredients via prioritization using HTS and guideline toxicology information.

Indexed as

Biological AssayEndocrine DisruptorsFungicides, IndustrialNitrilesToxicity TestsTriazolesUnited StatesEndocrine DisruptorsFungicides, IndustrialNitrilespropiconazolesysthanetriadimefonTriazolesEndocrine Disruptor Screening ProgramExpoCasthigh-throughput screeningmyclobutanilpropiconazoleTox21ToxCasttriadimefon

Identifiers

PMID27347635
PMCPMC5044773

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.